Updates on Outcome of AGM
Caplin Point Laboratories Ltd has submitted to BSE a copy of Proceedings of the 25th Annual General Meeting (AGM) of the Company held on September 12, 2016.14-09-2016
14-09-2016
Outcome of AGM
Caplin Point Laboratories Ltd has informed BSE that the 25th Annual General Meeting (AGM) of the Company was held on September 12, 2016.12-09-2016
Updates
Caplin Point Laboratories Ltd has informed BSE that US FDA inspection is to be conducted for the Company Sterile injectable site located near Gummidopoondi in third week of October. This Prior Approval Inspection(PAI) is in relation to an Injectable product ANDA being submitted with US FDA.09-09-2016
AGM on Sept 12, 2016
Caplin Point Laboratories Ltd has informed BSE that the 25th Annual General Meeting (AGM) of the Company will be held on September 12, 2016.25-08-2016
Fixes Book Closure for Final Dividend & AGM
Caplin Point Laboratories Ltd has informed BSE that the Register of Members & Share Transfer Books of the Company will remain closed from September 03, 2016 to September 12, 2016 (both days inclusive) for the purpose of Payment of Final Dividend & 25th Annual General Meeting (AGM) of the Company to be held on September 12, 2016.22-08-2016
We will continue to grow at 20-25%: Vivek Partheeban, Caplin Point Labs
"Over 90 per cent of our revenues are still coming from Latin America and in the next couple of years we see the same trend continuing."08-08-2016
Results Press Release for June 30, 2016
Caplin Point Laboratories Ltd has informed BSE about : 1. Result Press Release for the period ended June 30, 201605-08-2016
Standalone & Consolidated Financial Results, Limited Review Report for June 30, 2016
Caplin Point Laboratories Ltd has informed BSE about : 1. Standalone Financial Results for the period ended June 30, 20162. Consolidated Financial Results for the period ended June 30, 20163. Standalone Limited Review for the period ended June 30, 20164. Consolidated Limited Review for the period ended June 30, 201605-08-2016
Board approves Sub-division of equity shares
Caplin Point Laboratories Ltd has informed BSE that the Board of Directors of the Company at its meeting held on August 05, 2016, have approved the sub-division of existing Equity Shares of face value Rs. 10/- each into 5 (five) Equity Shares of face value of Rs. 2/- each, subject to the approval of members of the Company at the ensuing Annual General Meeting and Regulatory/ Statutory approvals.05-08-2016
Updates on ensuing Board Meeting on August 05, 2016
With reference to the earlier letter dated July 21, 2016 regarding Intimation of Board Meeting to be held on August 05, 2016, Caplin Point Laboratories Ltd has now informed BSE that the Board of Directors of the Company at their meeting to be held on August 05, 2016, will also consider, approve and take on record the Un-audited Financial Results of the Company for the quarter ended June 30, 2016.28-07-2016